Preconditioning of Bone Marrow Mesenchymal Stem Cells by Prolyl Hydroxylase Inhibition Enhances Cell Survival and Angiogenesis in Vitro and After Transplantation into the Ischemic Heart of Rats

Overview

Journal Stem Cell Res Ther

Publisher Biomed Central

Date 2014 Sep 27

PMID 25257482

Citations 52

Authors

Xian-Bao Liu

Jian-An Wang

Xiao-Ya Ji

Shan Ping Yu

Ling Wei

Affiliations

Soon will be listed here.

Abstract

Introduction: Poor cell survival and limited functional benefits have restricted the efficacy of bone marrow mesenchymal stem cells (BMSCs) in the treatment of myocardial infarction. We showed recently that hypoxia preconditioning of BMSCs and neural progenitor cells before transplantation can enhance the survival and therapeutic properties of these cells in the ischemic brain and heart. The present investigation explores a novel strategy of preconditioning BMSCs using the Hypoxia-inducible factor 1α (HIF-α) prolyl hydroxylase inhibitor dimethyloxalylglycine (DMOG) to enhance their survival and therapeutic efficacy after transplantation into infarcted myocardium.

Methods: BMSCs from green fluorescent protein transgenic rats were cultured with or without 1 mM DMOG for 24 hours in complete culture medium before transplantation. Survival and angiogenic factors were evaluated in vitro by trypan blue staining, Western blotting, and tube formation test. In an ischemic heart model of rats, BMSCs with and without DMOG preconditioning were intramyocardially transplanted into the peri-infarct region 30 minutes after permanent myocardial ischemia. Cell death was measured 24 hours after engraftment. Heart function, angiogenesis and infarct size were measured 4 weeks later.

Results: In DMOG preconditioned BMSCs (DMOG-BMSCs), the expression of survival and angiogenic factors including HIF-1α, vascular endothelial growth factor, glucose transporter 1 and phospho-Akt were significantly increased. In comparison with control cells, DMOG-BMSCs showed higher viability and enhanced angiogenesis in both in vitro and in vivo assays. Transplantation of DMOG-BMSCs reduced heart infarct size and promoted functional benefits of the cell therapy.

Conclusions: We suggest that DMOG preconditioning enhances the survival capability of BMSCs and paracrine effects with increased differentiation potential. Prolyl hydroxylase inhibition is an effective and feasible strategy to enhance therapeutic efficacy and efficiency of BMSC transplantation therapy after heart ischemia.

Citing Articles

YTHDC1 Mitigates Apoptosis in Bone Marrow Mesenchymal Stem Cells by Inhibiting and Augmenting Cardiac Function Following Myocardial Infarction.

Han W, Xiong W, Sun W, Liu W, Zhang Y, Li C Cell Transplant. 2024; 33:9636897241290910.

PMID: 39466658 PMC: 11528794. DOI: 10.1177/09636897241290910.

Priming mesenchymal stem cells to develop "super stem cells".

Haider K World J Stem Cells. 2024; 16(6):623-640.

PMID: 38948094 PMC: 11212549. DOI: 10.4252/wjsc.v16.i6.623.

Effect of Dimethyloxalylglycine on Stem Cells Osteogenic Differentiation and Bone Tissue Regeneration-A Systematic Review.

Dong Q, Fei X, Zhang H, Zhu X, Ruan J Int J Mol Sci. 2024; 25(7).

PMID: 38612687 PMC: 11011423. DOI: 10.3390/ijms25073879.

Therapeutic and immunomodulatory potentials of mesenchymal stromal/stem cells and immune checkpoints related molecules.

Hazrati A, Malekpour K, Khorramdelazad H, Rajaei S, Hashemi S Biomark Res. 2024; 12(1):35.

PMID: 38515166 PMC: 10958918. DOI: 10.1186/s40364-024-00580-2.

Mesenchymal Stem Cell-Derived Exosomal microRNAs in Cardiac Regeneration.

Bhaskara M, Anjorin O, Wang M Cells. 2023; 12(24).

PMID: 38132135 PMC: 10742005. DOI: 10.3390/cells12242815.

References

Behfar A, Yamada S, Crespo-Diaz R, Nesbitt J, Rowe L, Perez-Terzic C . Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol. 2010; 56(9):721-34. PMC: 2932958. DOI: 10.1016/j.jacc.2010.03.066. View

Liu X, Wang J, Ogle M, Wei L . Prolyl hydroxylase inhibitor dimethyloxalylglycine enhances mesenchymal stem cell survival. J Cell Biochem. 2009; 106(5):903-11. DOI: 10.1002/jcb.22064. View

Chacko S, Ahmed S, Selvendiran K, Kuppusamy M, Khan M, Kuppusamy P . Hypoxic preconditioning induces the expression of prosurvival and proangiogenic markers in mesenchymal stem cells. Am J Physiol Cell Physiol. 2010; 299(6):C1562-70. PMC: 3006322. DOI: 10.1152/ajpcell.00221.2010. View

Li S, Acevedo J, Wang L, Jiang H, Luo J, Pestell R . Mechanisms for progenitor cell-mediated repair for ischemic heart injury. Curr Stem Cell Res Ther. 2011; 7(1):2-14. PMC: 6544365. DOI: 10.2174/157488812798483449. View

Campagnoli C, Roberts I, Kumar S, Bennett P, Bellantuono I, Fisk N . Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood. 2001; 98(8):2396-402. DOI: 10.1182/blood.v98.8.2396. View

Braunwald E, Bristow M . Congestive heart failure: fifty years of progress. Circulation. 2000; 102(20 Suppl 4):IV14-23. DOI: 10.1161/01.cir.102.suppl_4.iv-14. View

Yu X, Chen D, Zhang Y, Wu X, Huang Z, Zhou H . Overexpression of CXCR4 in mesenchymal stem cells promotes migration, neuroprotection and angiogenesis in a rat model of stroke. J Neurol Sci. 2012; 316(1-2):141-9. DOI: 10.1016/j.jns.2012.01.001. View

Rey S, Luo W, Shimoda L, Semenza G . Metabolic reprogramming by HIF-1 promotes the survival of bone marrow-derived angiogenic cells in ischemic tissue. Blood. 2011; 117(18):4988-98. PMC: 3100705. DOI: 10.1182/blood-2010-11-321190. View

Iyer N, Kotch L, Agani F, Leung S, Laughner E, Wenger R . Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 1998; 12(2):149-62. PMC: 316445. DOI: 10.1101/gad.12.2.149. View

10.

Niagara M, Haider H, Jiang S, Ashraf M . Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart. Circ Res. 2007; 100(4):545-55. DOI: 10.1161/01.RES.0000258460.41160.ef. View

11.

Asikainen T, Waleh N, Schneider B, Clyman R, White C . Enhancement of angiogenic effectors through hypoxia-inducible factor in preterm primate lung in vivo. Am J Physiol Lung Cell Mol Physiol. 2006; 291(4):L588-95. DOI: 10.1152/ajplung.00098.2006. View

12.

Tang Y, Tang Y, Zhang Y, Qian K, Shen L, Phillips M . Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol. 2005; 46(7):1339-50. DOI: 10.1016/j.jacc.2005.05.079. View

13.

Kotch L, Iyer N, Laughner E, Semenza G . Defective vascularization of HIF-1alpha-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Dev Biol. 1999; 209(2):254-67. DOI: 10.1006/dbio.1999.9253. View

14.

Haider K, Ashraf M . Preconditioning approach in stem cell therapy for the treatment of infarcted heart. Prog Mol Biol Transl Sci. 2012; 111:323-56. DOI: 10.1016/B978-0-12-398459-3.00015-0. View

15.

Kohin S, Stary C, Howlett R, Hogan M . Preconditioning improves function and recovery of single muscle fibers during severe hypoxia and reoxygenation. Am J Physiol Cell Physiol. 2001; 281(1):C142-6. DOI: 10.1152/ajpcell.2001.281.1.C142. View

16.

Wei L, Fraser J, Lu Z, Hu X, Yu S . Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats. Neurobiol Dis. 2012; 46(3):635-45. PMC: 3353023. DOI: 10.1016/j.nbd.2012.03.002. View

17.

Misra M, Sarwat M, Bhakuni P, Tuteja R, Tuteja N . Oxidative stress and ischemic myocardial syndromes. Med Sci Monit. 2009; 15(10):RA209-219. View

18.

Kim S, Lee D, Yu L, Zhang H, Kim C, Kim J . Mesenchymal stem cells overexpressing GCP-2 improve heart function through enhanced angiogenic properties in a myocardial infarction model. Cardiovasc Res. 2012; 95(4):495-506. DOI: 10.1093/cvr/cvs224. View

19.

Lomb D, Straub J, Freeman R . Prolyl hydroxylase inhibitors delay neuronal cell death caused by trophic factor deprivation. J Neurochem. 2007; 103(5):1897-906. DOI: 10.1111/j.1471-4159.2007.04873.x. View

20.

Olson S, Pollock K, Kambal A, Cary W, Mitchell G, Tempkin J . Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington's disease. Mol Neurobiol. 2011; 45(1):87-98. PMC: 3259334. DOI: 10.1007/s12035-011-8219-8. View